

Adrian Alegre

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9763576/publications.pdf>

Version: 2024-02-01

115
papers

5,456
citations

126708

33
h-index

82410

72
g-index

118
all docs

118
docs citations

118
times ranked

4681
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study. <i>British Journal of Haematology</i> , 2022, 196, 639-648.	1.2	7
2	A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2022, 12, 68.	2.8	8
3	Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. <i>Haematologica</i> , 2021, 106, 1182-1187.	1.7	27
4	Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 757-767.	0.8	98
5	Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and Russia. <i>Oncology and Therapy</i> , 2021, 9, 139-151.	1.0	4
6	Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial. <i>Blood Cancer Journal</i> , 2021, 11, 101.	2.8	14
7	Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics. <i>British Journal of Haematology</i> , 2021, 194, 120-131.	1.2	27
8	Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 169.	2.8	2
9	Compassionate Use of Belantamab Mafodotin for Treatment of Patients with Relapsed/Refractory Multiple Myeloma Heavily Treated. Spanish Experience. <i>Blood</i> , 2021, 138, 3775-3775.	0.6	4
10	Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd. <i>Blood</i> , 2021, 138, 1829-1829.	0.6	12
11	Results of an Early Access Treatment Protocol of Daratumumab Monotherapy in Spanish Patients With Relapsed or Refractory Multiple Myeloma. <i>HemaSphere</i> , 2020, 4, e380.	1.2	3
12	Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. <i>Journal of Hematology and Oncology</i> , 2020, 13, 133.	6.9	171
13	Matching-adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligible. <i>EJHaem</i> , 2020, 1, 481-488.	0.4	0
14	Can COVID-19 cause severe neutropenia?. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 3348-3350.	0.2	16
15	Angioimmunoblastic T-cell lymphoma after acute myeloid leukemia: Alleged common pathogenesis. A case report and literature review. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 3494-3497.	0.2	0
16	Treatment with daratumumab in patients with relapsed/refractory AL amyloidosis: a multicentric retrospective study and review of the literature. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 163-167.	1.4	27
17	Intravenous Busulfan-Melphalan vs Melphalan as Preparative Regimen for Newly Diagnosed Multiple Myeloma: Long-Term Follow-Up of a Case-Control Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e287-e288.	0.2	0
18	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. <i>Lancet, The</i> , 2019, 394, 2096-2107.	6.3	435

#	ARTICLE	IF	CITATIONS
19	HORIZON (OP-106) Study of Melflufen in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Daratumumab and/or Pomalidomide: Updated Efficacy and Safety. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S329-S330.	0.2	2
20	Activity of Melflufen in RR MM Patients with Extramedullary Disease in the Phase 2 HORIZON Study (OP-106): Promising Results in a High-Risk Population. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e352-e353.	0.2	2
21	Efficacy of isatuximab/pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA-MM high-risk cytogenetics subgroup analysis. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e33.	0.2	7
22	Qip-Mass Spectrometry in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment. Blood, 2019, 134, 581-581.	0.6	14
23	Efficacy of Isatuximab with Pomalidomide and Dexamethasone in Elderly Patients with Relapsed/Refractory Multiple Myeloma: Icaria-MM Subgroup Analysis. Blood, 2019, 134, 1893-1893.	0.6	3
24	Abstract CT154: Melflufen in patients (pts) with relapsed/refractory multiple myeloma (RRMM) refractory to daratumumab (dara) and/or pomalidomide (pom) (OP-106)., 2019, , .		0
25	Impact of Modified Thalidomide Dosing in Bortezomib/Thalidomide/Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible: A Matching-Adjusted Indirect Comparison. Blood, 2019, 134, 4739-4739.	0.6	0
26	Heavy and Light Chain Monitoring in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment. Blood, 2019, 134, 1852-1852.	0.6	1
27	VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Definitive Results of a Randomized Phase 3 Pethema/GEM Study. Blood, 2018, 132, 126-126.	0.6	13
28	OP-106 Horizon " Melflufen Therapy for RRMM Patients Refractory to Daratumumab and/or Pomalidomide; Updated Results and First Report on PFS. Blood, 2018, 132, 600-600.	0.6	12
29	A Phase I Study of Molibresib (GSK525762), a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of a Phase I/II Open Label Single Agent Study in Subjects with Non-Hodgkin's Lymphoma (NHL). Blood, 2018, 132, 1682-1682.	0.6	12
30	Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials. Journal of Clinical Oncology, 2017, 35, 2900-2910.	0.8	248
31	Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma. Haematologica, 2016, 101, 872-878.	1.7	19
32	Dynamics of Hemorrhagic Events and Primary Hemostasis Deffects during Treatment with Ibrutinib. Real-Life Experience. Blood, 2016, 128, 4936-4936.	0.6	0
33	Bendamustine, bortezomib and prednisone for the treatment of newly diagnosed multiple myeloma patients: results of a prospective phase 2 Spanish/Pethema trial. Haematologica, 2015, 100, 1096-102.	1.7	19
34	Phase 1/1<sc>B</sc> trial of the heat shock protein 90 inhibitor <sc>NVP</sc>"<sc>AU</sc>922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma. Cancer, 2015, 121, 2185-2192.	2.0	51
35	Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. Haematologica, 2015, 100, 1327-1333.	1.7	68
36	Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma. Haematologica, 2015, 100, 1334-1339.	1.7	44

#	ARTICLE	IF	CITATIONS
37	Liposomal Doxorubicin in Aggressive B Cell Lymphoma Has Similar Efficacy to the Conventional Formulation: Results from a Retrospective Cohort Study. <i>Blood</i> , 2015, 126, 5106-5106.	0.6	1
38	Assessment of Clinical Differences Between Starting Antimyeloma Treatment at Biological Relapse or at Clinical Relapse: Preliminary Results of an Observational Prospective Registry. <i>Blood</i> , 2015, 126, 4231-4231.	0.6	0
39	Allogeneic Hematopoietic Stem Cell Transplant in Advanced Multiple Myeloma: Experience from a Single Center. <i>Blood</i> , 2015, 126, 5536-5536.	0.6	0
40	Zoledronic acid in the management of bone disease as a consequence of multiple myeloma: a review. <i>European Journal of Haematology</i> , 2014, 92, 181-188.	1.1	15
41	Persistent Benefit of VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Long-Term Follow-up of a Randomized Phase 3 Pethema/GEM Study. <i>Blood</i> , 2014, 124, 3457-3457.	0.6	2
42	Observational Prospective Registry for the Assessment of the Clinical Impact of Starting Anti-Myeloma Treatment at Biological Relapse. <i>Blood</i> , 2014, 124, 4765-4765.	0.6	0
43	Peripheral T/NK-Cell Lymphomas: Survival with Current Treatment Strategies. La Princesa University Hospital Single Experience. <i>Blood</i> , 2014, 124, 5897-5897.	0.6	0
44	Kinetics of Response to Bortezomib/Thalidomide/Dexamethasone (VTD) in Multiple Myeloma: Implications for the Choice and Design of Pretransplantation Induction Regimens. <i>Blood</i> , 2014, 124, 2108-2108.	0.6	0
45	Comparison of Assessment of Imaging Response with Magnetic Resonance (MR) and 18fdg-PET/TC in Multiple Myeloma (MM). Single Centre Experience. <i>Blood</i> , 2014, 124, 5707-5707.	0.6	0
46	Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Matched Comparison to a Melphalan-Only Approach. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 69-74.	2.0	60
47	Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 1055-1066.	5.1	710
48	Clinical applicability and prognostic significance of molecular response assessed by fluorescentâ€œ<sc>PCR</sc> of immunoglobulin genes in multiple myeloma. Results from a <sc>GEM</sc>/<sc>PETHEMA</sc> study. <i>British Journal of Haematology</i> , 2013, 163, 581-589.	1.2	27
49	Phase 2 Study Of Bendamustine, Bortezomib (Velcade) and Prednisone (BVP) For Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , 2013, 122, 2155-2155.	0.6	3
50	MM-003 Phase 3 Study Of Pomalidomide In Combination With Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM): POM + Lodex Is Beneficial For Elderly Patients (> 65 Years of Age). <i>Blood</i> , 2013, 122, 3198-3198.	0.6	2
51	Patient Outcomes By Prior Therapies and Depth Of Response: Analysis Of MM-003, a Phase 3 Study Comparing Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2013, 122, 686-686.	0.6	2
52	Efficacy and Safety Of Pomalidomide Plus Low-Dose Dexamethasone In Advanced Multiple Myeloma: Results Of Randomized Phase 2 and 3 Trials (MM-002/MM-003). <i>Blood</i> , 2013, 122, 3185-3185.	0.6	0
53	Evaluation of clinical use and effectiveness of darbepoetin alfa in cancer patients with chemotherapy-induced anemia. <i>Current Medical Research and Opinion</i> , 2012, 28, 57-67.	0.9	6
54	Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma. <i>Clinical Medicine Insights: Oncology</i> , 2012, 6, CMO.S7275.	0.6	8

#	ARTICLE	IF	CITATIONS
55	Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease. <i>Haematologica</i> , 2012, 97, 616-621.	1.7	19
56	High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. <i>Blood</i> , 2012, 119, 687-691.	0.6	274
57	Multiparameter Flow Cytometry Evaluation of Plasma Cell DNA Content and Proliferation in 595 Transplant-Eligible Patients with Myeloma Included in the Spanish GEM2000 and GEM2005 < 65y Trials. <i>American Journal of Pathology</i> , 2012, 181, 1870-1878.	1.9	22
58	Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. <i>Blood</i> , 2012, 120, 1589-1596.	0.6	429
59	Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience. <i>Leukemia and Lymphoma</i> , 2012, 53, 1714-1721.	0.6	29
60	Treatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairment. <i>Cancer Treatment Reviews</i> , 2012, 38, 1012-1019.	3.4	16
61	Maintenance Therapy After Stem-Cell Transplantation for Multiple Myeloma with Bortezomib/Thalidomide Vs. Thalidomide Vs. alfa2b-Interferon: Final Results of a Phase III Pethema/GEM Randomized Trial. <i>Blood</i> , 2012, 120, 334-334.	0.6	12
62	Preliminary Experience of the Spanish Compassionate Use Registry of Bendamustine in Patients with Relapsed and/or Refractory Multiple Myeloma. <i>Blood</i> , 2012, 120, 4035-4035.	0.6	2
63	Whole Bone Marrow (BM) Immunophenotypic Profiling for the Identification of Newly Diagnosed Symptomatic Multiple Myeloma (MM) Patients with an MGUS-Like Signature Associated with Long-Term Disease Control (LTDC). <i>Blood</i> , 2012, 120, 3949-3949.	0.6	0
64	Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. <i>Blood</i> , 2011, 118, 529-534.	0.6	183
65	Lenalidomide is effective for extramedullary disease in relapsed or refractory multiple myeloma. <i>European Journal of Haematology</i> , 2011, 87, 281-284.	1.1	23
66	Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients. <i>International Journal of Hematology</i> , 2011, 93, 351-360.	0.7	19
67	Multiparameter Flow Cytometry (MFC) Evaluation of Plasma Cell (PC) DNA Ploidy Status and Proliferative Rate in 595 Multiple Myeloma (MM) Patients (pts) Included in the Spanish GEM2000 and GEM2005 < 65years Trials: Clinical Value and Biological Insights,. <i>Blood</i> , 2011, 118, 3938-3938.	0.6	2
68	A Phase III PETHEMA/GEM Randomized Trial of Posttransplant (ASCT) Maintenance in Multiple Myeloma: Superiority of Bortezomib/Thalidomide Compared with Thalidomide and Alfa-2b Interferon,. <i>Blood</i> , 2011, 118, 3962-3962.	0.6	6
69	Smoldering Multiple Myeloma (SMM) At High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) As Induction Therapy Followed by Maintenance Therapy with Len Alone Vs No Treatment. <i>Blood</i> , 2011, 118, 991-991.	0.6	5
70	High-Risk Cytogenetics and Persistent Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) Predict Unsustained Complete Response (CR) After Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM). <i>Blood</i> , 2011, 118, 630-630.	0.6	0
71	Under Scope of the Current Redefinition Process of Optimal Response in Multiple Myeloma: Assesment of Molecular Response by Fluorescent PCR of Ig Genes Has Similar Applicability and Prognosis Impact to Immunophenotypic Response. (A GEM/PETHEMA study),. <i>Blood</i> , 2011, 118, 3951-3951.	0.6	1
72	Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. <i>Haematologica</i> , 2010, 95, 1913-1920.	1.7	101

#	ARTICLE	IF	CITATIONS
73	Mid term results after bone marrow laser revascularization for treating refractory angina. BMC Cardiovascular Disorders, 2010, 10, 42.	0.7	12
74	The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer, 2010, 116, 3807-3814.	2.0	118
75	Clonal evolution in patients with chronic lymphocytic leukemia. Leukemia and Lymphoma, 2010, 51, 1142-1143.	0.6	10
76	Analysis of Immunophenotypic Response (IR) by Multiparameter Flow Cytometry In 516 Myeloma Patients Included In Three Consecutive Spanish Trials. Blood, 2010, 116, 1910-1910.	0.6	2
77	Smoldering Multiple Myeloma (SMM) at High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) as Induction Therapy Followed by Maintenance Therapy with Len Alone Vs No Treatment. Blood, 2010, 116, 1935-1935.	0.6	4
78	Safety, Efficacy, and Quality-of-Life Study of Lenalidomide Plus Dexamethasone In Previously Treated Patients with Multiple Myeloma: The Spanish Experience. Blood, 2010, 116, 3045-3045.	0.6	2
79	A Phase III PETHEMA/GEM Study of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) In Multiple Myeloma: Superiority of VTD (Bortezomib/Thalidomide/Dexamethasone) Over TD and VBMCP/VBAD Plus Bortezomib. Blood, 2010, 116, 307-307.	0.6	19
80	The Addition of Rituximab to CVP (Bagley) + Interferon- γ as Induction Regimen, Significantly Increases Complete Remission Rates and Progression Free Survival In Intermediate-High Risk Follicular Lymphoma Patients (LNH-pro vs. LNH-pro-05 trial). Blood, 2010, 116, 2867-2867.	0.6	0
81	Laser Transmyocardial Revascularization (TMLR) Combined with Autologous Bone Marrow Cells (ABMC) for Diffuse Coronary Disease (DCD). Results In 19 Cases. Blood, 2010, 116, 1181-1181.	0.6	0
82	Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: a phase II trial. Leukemia and Lymphoma, 2009, 50, 216-222.	0.6	24
83	Newly acquired chromosome Abnormalities During Course of CLL: a Retrospective Collection Data From 2 Spanish Centers.. Blood, 2009, 114, 4384-4384.	0.6	0
84	Long Term Significance of Response in Multiple Myeloma After Stem Cell Transplantation.. Blood, 2009, 114, 1811-1811.	0.6	1
85	Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival. Journal of Clinical Oncology, 2008, 26, 5775-5782.	0.8	263
86	Evaluation of minimal residual disease in multiple myeloma patients by fluorescent- α -polymerase chain reaction: the prognostic impact of achieving molecular response. British Journal of Haematology, 2008, 142, 766-774.	1.2	52
87	Methylene blue- α -photoinactivated plasma <i>versus</i> quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura: a multicentric, prospective cohort study. British Journal of Haematology, 2008, 143, 39-45.	1.2	57
88	Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-. Haematologica, 2008, 93, 1001-1008.	1.7	36
89	Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica, 2008, 93, 560-565.	1.7	82
90	Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation. Haematologica, 2008, 93, 1343-1350.	1.7	18

#	ARTICLE	IF	CITATIONS
91	Final Results of a Phase II Trial with Plitidepsin (Aplidin) Alone and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2008, 112, 3700-3700.	0.6	6
92	Preliminary Results of CNTO 328, An Anti-Interleukin-6 Monoclonal Antibody, in Combination with Bortezomib in the Treatment of Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2008, 112, 867-867.	0.6	11
93	Phase II Pethema Trial of Alternating Bortezomib and Dexamethasone As Induction Regimen Before Autologous Stem-Cell Transplantation in Younger Patients With Multiple Myeloma: Efficacy and Clinical Implications of Tumor Response Kinetics. <i>Journal of Clinical Oncology</i> , 2007, 25, 4452-4458.	0.8	106
94	Veno-Occlusive Disease of the Liver after High-Dose Cyto-reductive Therapy with Busulfan and Melphalan for Autologous Blood Stem Cell Transplantation in Multiple Myeloma Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1448-1454.	2.0	83
95	Clinical Efficacy of Bortezomib Based Therapy in Plasma Cell Leukemias.. <i>Blood</i> , 2007, 110, 2726-2726.	0.6	2
96	Methylen Blue Photoinactivated Plasma vs Fresh Frozen Plasma in Thrombotic Thrombocytopenic Purpura Treatment: A Multicentric Prospective Cohort Study.. <i>Blood</i> , 2007, 110, 1318-1318.	0.6	0
97	Maintenance Treatment after Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) in Multiple Myeloma (MM) with a Unique Weekly Dose of Pegylated Interferon alpha2b (Pegintron®): Preliminary Clinical Results in 30 Patients of a Phase II Multicentric Study.. <i>Blood</i> , 2007, 110, 4822-4822.	0.6	0
98	Patients with Relapsed or Progressive Multiple Myeloma Treated with Lenalidomide in the Compassionate Use Program. Spanish Registry, Preliminary Analysis.. <i>Blood</i> , 2007, 110, 4821-4821.	0.6	0
99	Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. <i>Blood</i> , 2006, 108, 2165-2172.	0.6	373
100	Alternating Bortezomib and Dexamethasone as Induction Regimen Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Younger Patients with Multiple Myeloma: Results of a PETHEMA Phase II Trial.. <i>Blood</i> , 2006, 108, 3086-3086.	0.6	3
101	Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study. <i>Haematologica</i> , 2006, 91, 621-7.	1.7	39
102	Bortezomib is an efficient agent in plasma cell leukemias. <i>International Journal of Cancer</i> , 2005, 114, 665-667.	2.3	59
103	Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 698-708.	2.0	103
104	Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation. <i>British Journal of Haematology</i> , 2003, 121, 104-108.	1.2	90
105	Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34+ selected blood cells from HLA-identical siblings. <i>Blood</i> , 2002, 100, 724-727.	0.6	68
106	Second Mobilization and Collection of Peripheral Blood Progenitor Cells in Healthy Donors Is Associated with Lower CD34+Cell Yields. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2002, 11, 705-709.	1.8	16
107	Myeloablative Treatments for Multiple Myeloma: Update of a Comparative Study of Different Regimens Used in Patients from the Spanish Registry for Transplantation in Multiple Myeloma. <i>Leukemia and Lymphoma</i> , 2002, 43, 67-75.	0.6	45
108	Analysis of factors associated with low peripheral blood progenitor cell collection in normal donors. <i>Transfusion</i> , 2002, 42, 4-9.	0.8	87

#	ARTICLE	IF	CITATIONS
109	Deletion of sequences flanking the t(9;22) breakpoint: a secondary genetic event associated with loss of cytogenetic response to interferon in a Philadelphia-positive chronic myeloid leukaemia patient. <i>British Journal of Haematology</i> , 2002, 117, 617-619.	1.2	0
110	Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry. <i>Haematologica</i> , 2002, 87, 609-14.	1.7	65
111	Favourable effect of the combination of acute and chronic graft-versus-host disease on the outcome of allogeneic peripheral blood stem cell transplantation for advanced haematological malignancies. <i>British Journal of Haematology</i> , 2001, 114, 544-550.	1.2	23
112	Donor age-related differences in PBPC mobilization with rHuG-CSF. <i>Transfusion</i> , 2001, 41, 201-205.	0.8	50
113	Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma. <i>British Journal of Haematology</i> , 2000, 109, 138-147.	1.2	69
114	Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. <i>British Journal of Haematology</i> , 2000, 109, 438-446.	1.2	100
115	Stem Cell Factor in Combination With Filgrastim After Chemotherapy Improves Peripheral Blood Progenitor Cell Yield and Reduces Apheresis Requirements in Multiple Myeloma Patients: A Randomized, Controlled Trial. <i>Blood</i> , 1999, 94, 1218-1225.	0.6	2